罗氟司特乳膏与本维莫德的比较？

Both Benvimod and Benvimod are suitable for the treatment of psoriasis, but they are different in terms of drug indications, mechanism of action, and therapeutic effects. It is recommended that patients choose drugs suitable for their condition under the guidance of a doctor.

Drug indications

Roflumilast cream is mainly used for mild to moderate plaque psoriasis and is suitable for topical treatment of plaque psoriasis in patients aged 12 years and above, including intertrigo areas. Benvimod cream is indicated for the topical treatment of mild to moderately stable psoriasis vulgaris in adults.

Mechanism of action

Roflumilast cream is an inhibitor of phosphodiesterase 4 (PDE4). By inhibiting the activity of PDE4, it reduces the degradation of intracellular cAMP, thereby increasing the level of intracellular cAMP. It can inhibit the release of various cytokines and inflammatory mediators in the inflammatory response, reduce inflammatory symptoms, and play a role in treating psoriasis. Roflumilast cream showed promising efficacy in the treatment of plaque psoriasis in two multicenter, randomized, double-blind, vehicle-controlled trials.

Benvimod cream can inhibit the migration and infiltration of inflammatory cells, abnormal differentiation and proliferation of keratinocytes, the release of inflammatory cytokines, neovascularization and vasodilation related to psoriasis.

Usage and dosage

Roflumilast cream is applied to the affected area. It is not for eye, oral or vaginal use. Wash your hands immediately after use.

Benvimod cream is applied evenly to the affected area twice daily, morning and evening. The maximum daily dosage cannot be greater than 6g, the treatment area cannot be greater than 10%, and the maximum dosage cannot be greater than 12 weeks.

Therapeutic effect

Once-daily 0.3% roflumilast cream, a potent phosphodiesterase 4 inhibitor, was shown to be effective and well-tolerated in a Phase 2b trial in patients with psoriasis.

One study evaluated the efficacy of 0.3% roflumilast cream in 2 patients with plaque psoriasis. Two phase 3, randomized, double-blind, controlled, multicenter trials were conducted. Patients aged 2 years or older with plaque psoriasis (involving 2% to 20% of body surface area) were included in the study. Patients were randomized in a 2:1 ratio to receive 0.3% roflumilast cream or vehicle cream once daily for 8 weeks.

The primary efficacy endpoint was investigator global assessment (IGA) success at Week 8 (clear or nearly clear plus ≥2-grade improvement from baseline [score range, 0-4]), analyzed using the Cochran-Mantel-Haenszel test. There were nine secondary outcomes, including interchondral IGA success, a 75% reduction in Psoriasis Area and Severity Index (PASI) score, a worst itch numeric rating scale score of 4 points or greater at baseline, and a 4-point reduction at week 8 (WI-NRS success).

Results: Among 881 participants, the mean IGA scores were 2.9 for roflumilast and 2.9 for vehicle in Trial 1 and 2.9 for roflumilast and 2.9 for vehicle in Trial 2. At week 8, IGA was significantly higher in the roflumilast-treated group than in the vehicle-treated group (Trial 1: 42.4% vs. 6.1%, Trial 2: 37.5% vs. 6.9%). Statistically significant differences in favor of roflumilast versus vehicle were observed in 8 of 9 secondary endpoints in Trial 1 and 9 in Trial 2, including interchondral IGA success rate, 75% reduction in PASI score, and WI-NRS success rate (67.5% vs. 26.8%).

It was concluded that in patients with chronic plaque psoriasis, treatment with 0.3% roflumilast cream for 8 weeks resulted in better clinical outcomes than vehicle cream.

Benvimod cream is clinically effective in treating mild to moderate psoriasis vulgaris in adults. It can effectively inhibit lymphocyte-specific protein tyrosine kinase, inhibit the release of inflammatory factors, inflammatory cell migration, infiltration, keratinization, abnormal cell differentiation and proliferation, alleviate the clinical symptoms of psoriasis patients, and reduce recurrence.

Summary

In general, roflumilast cream and benivimod cream are both drugs for the treatment of psoriasis, but their mechanisms of action and therapeutic effects are different. When choosing a drug, you need to choose it based on your condition and your doctor's advice.

Recommended related articles: